Concepedia

Publication | Open Access

Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the <scp>DEPICT</scp> ‐2 study): 52‐week results from a randomized controlled trial

DOIFull Paper Access

63

Citations

13

References

2020

Year

Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F. Scheerer, Nayyar Iqbal, Paresh Dandona
Diabetes Obesity and Metabolism

Abstract

Dapagliflozin led to long-term reductions in HbA1c and body weight in adults with T1D, but increased DKA risk compared with placebo.

References

YearCitations

Page 1